Lyra Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LYRA research report →
Companylyratherapeutics.com
Lyra Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
- CEO
- Carmichael S. Roberts Jr.
- IPO
- 2020
- Employees
- 30
- HQ
- Watertown, MA, US
Price Chart
Valuation
- Market Cap
- $781.13K
- P/E
- -0.24
- P/S
- 1.96
- P/B
- -0.64
- EV/EBITDA
- -0.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -7794.47%
- Net Margin
- -7266.08%
- ROE
- 1211.14%
- ROIC
- -98.78%
Growth & Income
- Revenue
- $398.00K · -74.05%
- Net Income
- $-28,919,000 · 69.05%
- EPS
- $-18.62 · -1202.10%
- Op Income
- $-31,022,000
- FCF YoY
- 59.95%
Performance & Tape
- 52W High
- $37.50
- 52W Low
- $0.44
- 50D MA
- $1.82
- 200D MA
- $5.95
- Beta
- 0.69
- Avg Volume
- 106.35K
Get TickerSpark's AI analysis on LYRA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Smith W Bradford | sell | 640 |
| Apr 1, 26 | Palasis Maria | sell | 2,000 |
| Apr 1, 26 | Cavalier Jason | sell | 667 |
| Jan 6, 26 | Cavalier Jason | sell | 769 |
| Jan 6, 26 | Palasis Maria | sell | 1,702 |
| Nov 11, 25 | PERCEPTIVE ADVISORS LLC | sell | 4,783 |
| Nov 12, 25 | PERCEPTIVE ADVISORS LLC | sell | 7,862 |
| Nov 13, 25 | PERCEPTIVE ADVISORS LLC | sell | 28,597 |
| Nov 11, 25 | PERCEPTIVE ADVISORS LLC | sell | 537 |
| Nov 12, 25 | PERCEPTIVE ADVISORS LLC | sell | 883 |
Our LYRA Coverage
We haven't published any research on LYRA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LYRA Report →